FIBROBLAST GROWTH-FACTOR IN THE EYE AND PROSPECTS FOR ITS THERAPEUTIC USE

被引:16
|
作者
TRIPATHI, RC
KOLLI, SP
TRIPATHI, BJ
机构
[1] Department of Ophthalmology and Visual Science, University of Chicago, Chicago
关键词
anti‐FGF antibodies; corneal endothelium injury; extracellular matrix; glaucoma surgery; macular degeneration; mechanism of action; neovascular glaucoma; primary open‐angle glaucoma; protamine sulfate; transforming growth factor‐beta; vitreoretinopathy;
D O I
10.1002/ddr.430190303
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fibroblast growth factor (FGF) is a monomeric mitogenic protein that exists as an acidic and a basic form and is distributed widely in tissues of the eye. Because FGF interacts with the cells and with the extracellular matrix, it has potential as a therapeutic agent, either alone or in combination with other agents such as epidermal growth factor, in promoting healing of corneal wounds, in restoring corneal endothelial cell loss due to dystrophic, degenerative, and surgical insults, as well as in regenerating lens cells after cataract surgery. Excess FGF probably plays a significant role in the pathogenesis of blinding disorders of the eye such as neovascular glaucoma, age‐related macular degeneration, and proliferative diabetic vitreoretinopathy, as well as failure of surgical filtering procedures for glaucoma. The use of transforming growth factor‐beta, anti‐FGF antibodies, and other blocking agents in the treatment of such diseases seems logical. Copyright © 1990 Wiley‐Liss, Inc.
引用
收藏
页码:225 / 237
页数:13
相关论文
共 50 条